Skip to main content
Voting Is Now Open for 2024–2025 U.S. News & World Report Best Hospitals Learn How

TAS1440 +/- All-Trans Retinoic Acid (ATRA) in Relapsed/Refractory AML

A first of its kind, Phase 1 multi-center study for Relapsed or Refractory Acute Myeloid Leukemia using investigational drug TAS1440 by itself, and in combination with All-Trans Retinoic Acid (ATRA). The study will test the safety, pharmacokinetics, and preliminary activity of TAS1440, as an investigational single agent alone, or in combination with All-Trans Retinoic Acid (ATRA) in subjects with Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML).

Drug: TAS1440 as an investigational single agent and in combination with ATRA

Inclusion: Histological confirmation of AML for whom all other available conational therapies have failed

Principal Investigator: Asya Nina Varshavsky-Yanovsky, MD, PhD

Protocol: 20-1043 / IRB20-1043 - ClinicalTrials.gov

More Information: Nicole.Ahrens@fccc.edu or 215-214-3173